{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:46:49Z","timestamp":1791082009313,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Faculty of Pharmacy, Chiang Mai University, Thailand"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.critrevonc.2017.02.017","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T10:16:36Z","timestamp":1487672196000},"page":"113-125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"112","author":[{"given":"Jukapun","family":"Yoodee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unchalee","family":"Permsuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mantiwee","family":"Nimworapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2017.02.017_bib0005","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/956785","article-title":"Efficacy of olanzapine combined therapy for patients receiving highly emetogenic chemotherapy resistant to standard antiemetic therapy","author":"Abe","year":"2015","journal-title":"BioMed Res. Int."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.02.017_bib0010","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00520-015-2829-z","article-title":"Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial","volume":"24","author":"Abe","year":"2016","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2017.02.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3439707","article-title":"The efficacy safety, and cost benefit of olanzapine versus aprepitant in highly emetogenic chemotherapy: a pilot study from south India","author":"Babu","year":"2016","journal-title":"Chemother. Res. Pract."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.02.017_bib0020","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s12094-012-0818-y","article-title":"Chemotherapy-induced nausea and vomiting: pathophysiology and therapeutic principles","volume":"14","author":"Bayo","year":"2012","journal-title":"Clin. Transl. Oncol."},{"issue":"27","key":"10.1016\/j.critrevonc.2017.02.017_bib0025","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.02.017_bib0030","first-page":"24","article-title":"an antiemetic option for chemotherapy-induced nausea and vomiting","volume":"5","author":"Brafford","year":"2014","journal-title":"J. Adv. Pract. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.02.017_bib0035","first-page":"349","article-title":"Effectiveness of olanzapine for the treatment of breakthrough chemotherapy induced nausea and vomiting","volume":"97","author":"Chanthawong","year":"2014","journal-title":"J. Med. Assoc. Thai."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.02.017_bib0040","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1007\/s00520-016-3075-8","article-title":"Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis","volume":"24","author":"Chiu","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.02.017_bib0045","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00520-015-3000-6","article-title":"Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review","volume":"24","author":"Chow","year":"2016","journal-title":"Support. Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.02.017_bib0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/phar.1703","article-title":"Emerging role of olanzapine for prevention and treatment of chemotherapy-induced nausea and vomiting","volume":"36","author":"DeRemer","year":"2016","journal-title":"Pharmacotherapy"},{"issue":"10","key":"10.1016\/j.critrevonc.2017.02.017_bib0055","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"},{"issue":"2 Suppl","key":"10.1016\/j.critrevonc.2017.02.017_bib0060","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/107327481201902s03","article-title":"Patient-centered management of chemotherapy-induced nausea and vomiting","volume":"19","author":"Grunberg","year":"2012","journal-title":"Cancer Control"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.02.017_bib0065","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1200\/JCO.2015.64.3635","article-title":"Antiemetics: American society of clinical oncology focused guideline update","volume":"34","author":"Hesketh","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2017.02.017_bib0070","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1002\/cncr.11408","volume":"97","author":"Hickok","year":"2003","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.critrevonc.2017.02.017_bib0075","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJM198110153051609","article-title":"Emesis as a critical problem in chemotherapy","volume":"305","author":"Laszlo","year":"1981","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.02.017_bib0080","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jpainsymman.2013.05.003","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: a randomized, double-blind, placebo-controlled study","volume":"47","author":"Mizukami","year":"2014","journal-title":"J. Pain Symptom Manag."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.02.017_bib0085","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/0885-3924(91)90011-R","article-title":"Predicting development of anticipatory nausea in cancer patients: prospective examination of eight clinical characteristics","volume":"6","author":"Morrow","year":"1991","journal-title":"J. Pain Symptom Manag."},{"issue":"8","key":"10.1016\/j.critrevonc.2017.02.017_bib0090","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/j.clinthera.2015.05.312","article-title":"Olanzapine, an effective and affordable adjuvant in prophylaxis for chemotherapy induced nausea and vomiting on platinum based chemotherapy patients","volume":"37","author":"Mukhopadhyay","year":"2015","journal-title":"Clin. Ther."},{"key":"10.1016\/j.critrevonc.2017.02.017_bib0095","article-title":"National comprehensive cancer network: antiemesis","volume":"2","author":"NCCN","year":"2015","journal-title":"Clin. Pract. Guidel. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2017.02.017_bib0100","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00520-004-0755-6","article-title":"A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study","volume":"13","author":"Navari","year":"2005","journal-title":"Support. Care Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2017.02.017_bib0105","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s00520-007-0248-5","article-title":"A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study","volume":"15","author":"Navari","year":"2007","journal-title":"Support. Care Cancer"},{"issue":"5","key":"10.1016\/j.critrevonc.2017.02.017_bib0110","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J. Support. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2017.02.017_bib0115","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support. Care Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2017.02.017_bib0120","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-Induced nausea and vomiting","volume":"325","author":"Navari","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.02.017_bib0125","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2165\/00003495-200969050-00002","article-title":"Pharmacological management of chemotherapy-induced nausea and vomiting: focus on recent developments","volume":"69","author":"Navari","year":"2009","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.critrevonc.2017.02.017_bib0130","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s005200050078","article-title":"Effect of post chemotherapy nausea and vomiting on health-related quality of life: the Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group","volume":"5","author":"Osoba","year":"1997","journal-title":"Support. Care Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2017.02.017_bib0135","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S0885-3924(02)00391-3","article-title":"A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain","volume":"23","author":"Passik","year":"2002","journal-title":"J. Pain Symptom Manag."},{"issue":"5","key":"10.1016\/j.critrevonc.2017.02.017_bib0140","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0885-3924(03)00078-2","article-title":"A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients","volume":"25","author":"Passik","year":"2003","journal-title":"J. Pain Symptom Manag."},{"issue":"3","key":"10.1016\/j.critrevonc.2017.02.017_bib0145","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1081\/CNV-200029066","article-title":"A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study","volume":"22","author":"Passik","year":"2004","journal-title":"Cancer Investig."},{"issue":"4","key":"10.1016\/j.critrevonc.2017.02.017_bib0150","first-page":"232","article-title":"Chemotherapy-induced nausea and vomiting: optimizing prevention and management","volume":"5","author":"Rao","year":"2012","journal-title":"Am. Health Drug Benefits"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2017.02.017_bib0155","doi-asserted-by":"crossref","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.017_bib0160","article-title":"A randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting","author":"Shumway","year":"2009","journal-title":"ASCO Annual Meeting Proceedings"},{"key":"10.1016\/j.critrevonc.2017.02.017_bib0165","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.critrevonc.2015.12.001","article-title":"Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review","volume":"99","author":"Sommariva","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1083","key":"10.1016\/j.critrevonc.2017.02.017_bib0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1136\/postgradmedj-2014-132969","article-title":"Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines","volume":"92","author":"Tageja","year":"2016","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.critrevonc.2017.02.017_bib0175","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/1756-9966-28-131","article-title":"Clinical research of Olanzapine for prevention of chemotherapy-induced nausea and vomiting","volume":"28","author":"Tan","year":"2009","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.critrevonc.2017.02.017_bib0180","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jpainsymman.2006.10.015","article-title":"Symptom prevalence in patients with incurable cancer: a systematic review","volume":"34","author":"Teunissen","year":"2007","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.critrevonc.2017.02.017_bib0185","article-title":"A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting","author":"Wang","year":"2014","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2017.02.017_bib0190","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s12013-014-0489-0","article-title":"Effectiveness of olanzapine combined with ondansetron in prevention of chemotherapy-induced nausea and vomiting of non-small cell lung cancer","volume":"72","author":"Wang","year":"2015","journal-title":"Cell Biochem. Biophys."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816302943?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816302943?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T22:38:05Z","timestamp":1538779085000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816302943"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":38,"alternative-id":["S1040842816302943"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.017","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}